These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 25753327

  • 1. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings.
    Rizvi H, Butler T, Calaminici M, Doobaree IU, Nandigam RC, Bennett D, Provan D, Newland AC.
    Br J Haematol; 2015 May; 169(4):590-4. PubMed ID: 25753327
    [Abstract] [Full Text] [Related]

  • 2. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
    Ghanima W, Junker P, Hasselbalch HC, Boiocchi L, Geyer JT, Feng X, Gudbrandsdottir S, Orazi A, Bussel JB.
    Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.
    Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, Bussel JB.
    Haematologica; 2014 May; 99(5):937-44. PubMed ID: 24463212
    [Abstract] [Full Text] [Related]

  • 4. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.
    Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT.
    Mod Pathol; 2012 Jan; 25(1):65-74. PubMed ID: 21841770
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
    Brynes RK, Orazi A, Theodore D, Burgess P, Bailey CK, Thein MM, Bakshi KK.
    Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
    [Abstract] [Full Text] [Related]

  • 6. Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.
    Ghanima W, Boiocchi L, Lee CS, Feng X, Geyer JT, Gudbrandsdottir S, Orazi A, Junker P, Bussel JB.
    Platelets; 2019 Jul; 30(2):222-228. PubMed ID: 29293383
    [Abstract] [Full Text] [Related]

  • 7. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
    Kirito K, Komatsu N.
    Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
    Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M.
    Blood; 2009 Oct 29; 114(18):3748-56. PubMed ID: 19671919
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide study.
    Ettrup MS, Jensen AØ, Engebjerg MC, Farkas DK, Nørgaard M, Cha S, Zhao S, Johansen P, Sørensen HT.
    Am J Hematol; 2010 Dec 29; 85(12):930-4. PubMed ID: 20981681
    [Abstract] [Full Text] [Related]

  • 10. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, Michel M.
    Br J Haematol; 2014 Jun 29; 165(6):865-9. PubMed ID: 24725224
    [Abstract] [Full Text] [Related]

  • 11. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
    Leung T, Lokan J, Turner P, Smith C.
    Pathology; 2011 Aug 29; 43(5):520-2. PubMed ID: 21753725
    [No Abstract] [Full Text] [Related]

  • 12. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
    Nazy I, Kelton JG, Moore JC, Clare R, Horsewood P, Smith JW, Ivetic N, D'Souza V, Li N, Arnold DM.
    Br J Haematol; 2018 Apr 29; 181(2):234-241. PubMed ID: 29532903
    [Abstract] [Full Text] [Related]

  • 13. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT, Fernández Bello I, Arias-Salgado EG, Rivas Pollmar MI, Jiménez Yuste V, Martín Salces M, Butta NV.
    Thromb Haemost; 2014 Jul 03; 112(1):65-72. PubMed ID: 24500066
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P.
    Eur J Haematol; 2013 Nov 03; 91(5):423-36. PubMed ID: 23927437
    [Abstract] [Full Text] [Related]

  • 15. Myelofibrosis in ITP and with TPO-RA - time to rethink?
    Thachil J.
    Platelets; 2021 Oct 03; 32(7):995-996. PubMed ID: 32835570
    [No Abstract] [Full Text] [Related]

  • 16. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
    Liebman HA, Pullarkat V.
    Hematology Am Soc Hematol Educ Program; 2011 Oct 03; 2011():384-90. PubMed ID: 22160062
    [Abstract] [Full Text] [Related]

  • 17. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
    Gernsheimer TB.
    Hematology Am Soc Hematol Educ Program; 2008 Oct 03; ():219-26. PubMed ID: 19074086
    [Abstract] [Full Text] [Related]

  • 18. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists.
    Thachil J, Bagot C, Bradbury C, Cooper N, Lester W, Grainger JD, Lowe G, Evans G, Talks K, Sibson K, Garg M, Murphy MF, Watson HG, Bolton-Maggs PHB, Watson S, Scully M, Provan D, Newland A, Hill QA.
    Br J Haematol; 2018 Feb 03; 180(4):591-594. PubMed ID: 27879997
    [No Abstract] [Full Text] [Related]

  • 19. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.
    Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R.
    Am J Hematol; 2018 Jan 03; 93(1):58-64. PubMed ID: 28983953
    [Abstract] [Full Text] [Related]

  • 20. A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.
    Brynes RK, Wong RS, Thein MM, Bakshi KK, Burgess P, Theodore D, Orazi A.
    Acta Haematol; 2017 Jan 03; 137(2):66-72. PubMed ID: 28006767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.